Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Tumori is Scopus-indexed (Q3, CiteScore 4), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Wichtig Publishing Srl.
Checked against the index lists dated .
ISSN 0300-8916Verify ISSN ↗2038-2529Verify ISSN ↗
Publisher: Wichtig Publishing Srl
Cost to publish: About US$4,150 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 218 / 428 | 49th | Q3 |
| Cancer Research | 158 / 233 | 32nd | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1946–present, best quartile Q3, CiteScore 4.
Tumori is Q3 in Oncology (rank 218 of 428) and Q3 in Cancer Research (rank 158 of 233), by CiteScore 2025.
Tumori is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4, which places it in quartile Q3 at the 49th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.574, quartile Q2, with an H-index of 60.
The publisher lists an article processing charge of about US$4,150 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Tumori is published by Wichtig Publishing Srl. Its print ISSN is 0300-8916 and its online ISSN is 2038-2529.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Tumori has an h-index of 74 and a 2-year mean of 1.08 citations per paper (OpenAlex). Its Scopus CiteScore is 4, quartile Q3. On 2-year citations it ranks #286 of 424 Scopus journals in Oncology.
Tumori published 61 papers in 2025; its busiest recent year was 2020 with 175. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2025–2026), authors are most often from Italy (61.3%), China (17.2%) and Türkiye (4.4%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.2 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.